Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK2 | P51955 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
| ▸ | SELP | P16109 | 1/20 | 0.41 |
| ▸ | SELE | P16581 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3104224 | 0.85 | NR1H4 (0.56) | NR1H4SELPSELEHPSEKMT2A | |
| SCHEMBL14148255 | 0.84 | CSNK2A1 (0.48) | NEK2NR1H4SELPSELEHPSE | |
| SCHEMBL10391003 | 0.84 | ALDH1A1 (0.58) | NPSR1KMT2ASMN1; SMN2L3MBTL1MAPT | |
| SCHEMBL11509820 | 0.83 | HPSE (0.50) | NR1H4SELPSELENPSR1HPSE | |
| SCHEMBL693860 | 0.82 | SLC7A5 (0.54) | KMT2ASMN1; SMN2LMNAHTTMAPT | |
| SCHEMBL12472792 | 0.82 | MAPT (0.51) | NEK2NR1H4NPSR1KMT2ALMNA | |
| SCHEMBL10754184 | 0.82 | ALDH1A1 (0.56) | SMN1; SMN2LMNAHTTMAPTHDAC1 | |
| SCHEMBL6509671 | 0.82 | ALDH1A1 (0.46) | SLC7A5POLB | |
| SCHEMBL21700167 | 0.81 | APP (0.37) | NR1H4SELPSELENPSR1HPSE | |
| SCHEMBL22317162 | 0.81 | NEK2 (0.46) | NEK2NR1H4SELPSELEHPSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111153816-A | Preparation method of tomoxetine | 北京万全德众医药生物技术有限公司 | 2020-05-15 | — | — | CN | disclosed |
| CN-111153816-A | Preparation method of tomoxetine | 北京万全德众医药生物技术有限公司 | 2020-05-15 | — | — | CN | disclosed |
| EP-2480247-B1 | NOVEL NPR-B AGONISTS | SHIRE ORPHAN THERAPIES GMBH (DE) | 2020-02-12 | — | — | EP | disclosed |
| US-9822147-B2 | Methods of treating ophthalmic diseases using NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2017-11-21 | — | — | US | disclosed |
| US-20170313743-A1 | NPR-B Agonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-11-02 | — | — | US | disclosed |
| US-9745344-B2 | NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2017-08-29 | — | — | US | disclosed |
| US-20170101440-A1 | METHODS OF TREATING OPHTHALMIC DISEASES USING NPR-B AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-13 | — | — | US | disclosed |
| US-20160194357-A1 | Novel NPR-B Agonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-07-07 | — | — | US | disclosed |
| US-9187525-B2 | Methods of treating ophthalmic diseases using NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| US-9169293-B2 | NPR-B agonists | Shire Orphan Thereapies GmbH (DE) | 2015-10-27 | — | — | US | disclosed |
| US-8101186-B2 | Peptides that block the binding of IgG to FcRn | SYNTONIX PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110230639-A1 | IMMUNOMODULATORY PEPTIDES | SYNTONIX PHARMACEUTICALS INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110059889-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG TO FcRn | SYNTONIX PHARMACEUTICALS, INC. | 2011-03-10 | — | — | US | disclosed |
| US-7759459-B2 | Fluorescent assays for protein kinases | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759459-B2 | Fluorescent assays for protein kinases | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2010-07-20 | — | — | US | disclosed |
| WO-2009020867-A2 | IMMUNOMODULATORY PEPTIDES | SYNTONIX PHARMACEUTICALS, INC. (US) | 2009-02-12 | — | — | WO | disclosed |
| US-20080064643-A1 | Myd88 Homodimerization Inhibitors | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-03-13 | — | — | US | disclosed |
| US-20080064643-A1 | Myd88 Homodimerization Inhibitors | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-03-13 | — | — | US | disclosed |
| US-20070254831-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn | BIOGEN HEMOPHILIA INC. | 2007-11-01 | — | — | US | disclosed |
| US-20070254831-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn | BIOGEN HEMOPHILIA INC. | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313743-A1 | NPR-B Agonists | NPR1, NPR3, NPBWR1 | NEK2 1215/4885NR1H4 449/4885SELP 1628/4885 |
| US-20110059889-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG TO FcRn | FCGRT, FCGR3B, FCGR1A | NEK2 4730/4885NR1H4 1159/4885SELP 48/4885 |
| US-20160194357-A1 | Novel NPR-B Agonists | NPR1, NPR3, NPBWR1 | NEK2 1314/4885NR1H4 617/4885SELP 1705/4885 |
| US-20070254831-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn | FCGRT, FCGR3B, FCGR1A | NEK2 4730/4885NR1H4 1159/4885SELP 48/4885 |
| US-20170101440-A1 | METHODS OF TREATING OPHTHALMIC DISEASES USING NPR-B AGONISTS | NPR1, EDNRB, NPR3 | NEK2 2133/4885NR1H4 431/4885SELP 1839/4885 |
| US-20080064643-A1 | Myd88 Homodimerization Inhibitors | MYD88, TLR4, TLR6 | NEK2 3445/4885NR1H4 1101/4885SELP 2763/4885 |
| US-20110230639-A1 | IMMUNOMODULATORY PEPTIDES | FCGRT, FCGR3B, FCGR2A | NEK2 4867/4885NR1H4 2124/4885SELP 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.